U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Resources for Information | Approved Drugs
  6. FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia
  1. Resources for Information | Approved Drugs

FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia

On December 21, 2017, the Food and Drug Administration granted regular approval to hydroxyurea (Siklos, Addmedica) to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients from 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises.

This is the first FDA approval of hydroxyurea for use in pediatric patients with sickle cell disease.

Approval was based on data from an open-label single-arm trial, the European Sickle Cell Disease Cohort study (ESCORT HU, NCT02516579), of 405 pediatric patients with sickle cell disease from 2-18 years of age, of which 141 had not been previously treated with hydroxyurea prior to enrollment. Among this pediatric population analyzable for efficacy (n=141), Siklos use resulted in an increase in hemoglobin F. The percentage of patients with at least one vaso-occlusive episode, one episode of acute chest syndrome, one hospitalization due to SCD or one blood transfusion decreased after 12 months of hydroxyurea treatment.

Most common adverse reactions to Siklos (incidence >10%) include infections and neutropenia.

The recommended initial dose of hydroxyurea is 20 mg/kg once daily.

Full prescribing information is available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf.

FDA granted priority review and Orphan Drug designation to this application. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics, available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

Follow the Oncology Center of Excellence on Twitter @FDAOncology.disclaimer icon

Check out recent approvals at the OCE’s podcast, Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.), available at www.fda.gov/DISCO.

Back to Top